MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-17-1507

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2018

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo Viktoria, Valko Zsuzsanna, Kovacs Ildiko, Ozsvar Judit, Hoda Mir Alireza, Klikovits Thomas, Lakatos Dora, Czirok Andras, Garay Tamas, Stiglbauer Alexander, Helbich Thomas H, Gröger Marion, Tovari Jozsef, Klepetko Walter, Pirker Christine, Grusch Michael, Berger Walter, Hilberg Frank, Hegedus Balazs, Dome Balazs

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Purpose: Malignant pleural mesothelioma (MPM) is an aggressive thoracic tumor type with limited treatment options and poor prognosis. The angiokinase inhibitor nintedanib has shown promising activity in the LUME-Meso phase II MPM trial and thus is currently being evaluated in the confirmatory LUME-Meso phase III trial. However, the anti-MPM potential of nintedanib has not been studied in the preclinical setting.Experimental

Design

We have examined the antineoplastic activity of nintedanib in various in vitro and in vivo models of human MPM.

Results

Nintedanib's target receptors were (co)expressed in all the 20 investigated human MPM cell lines. Nintedanib inhibited MPM cell growth in both short- and long-term viability assays. Reduced MPM cell proliferation and migration and the inhibition of Erk1/2 phosphorylation were also observed upon nintedanib treatment in vitro Additive effects on cell viability were detected when nintedanib was combined with cisplatin, a drug routinely used for systemic MPM therapy. In an orthotopic mouse model of human MPM, survival of animals receiving nintedanib per os showed a favorable trend, but no significant benefit. Nintedanib significantly reduced tumor burden and vascularization and prolonged the survival of mice when it was administered intraperitoneally. Importantly, unlike bevacizumab, nintedanib demonstrated significant in vivo antivascular and antitumor potential independently of baseline VEGF-A levels.

Conclusions

Nintedanib exerts significant antitumor activity in MPM both in vitro and in vivo These data provide preclinical support for the concept of LUME-Meso trials evaluating nintedanib in patients with unresectable MPM. Clin Cancer Res; 24(15); 3729-40. ©2018 AACR.

Для цитирования: Laszlo Viktoria, Valko Zsuzsanna, Kovacs Ildiko, Ozsvar Judit, Hoda Mir Alireza, Klikovits Thomas, Lakatos Dora, Czirok Andras, Garay Tamas, Stiglbauer Alexander, Helbich Thomas H, Gröger Marion, Tovari Jozsef, Klepetko Walter, Pirker Christine, Grusch Michael, Berger Walter, Hilberg Frank, Hegedus Balazs, Dome Balazs. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. DOI: 10.1158/1078-0432.ccr-17-1507.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.